PAREXEL Launches Patient Sensor Solution To Transform Clinical Trial Data Collection
Comprehensive wearables and sensors solution, powered by the Perceptive MyTrials® Analytics platform, creates greater efficiencies for biopharmaceutical companies
(firmenpresse) - LONDON, March 30, 2017 – PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced the launch of its patient sensor solution, a new offering that securely captures, transmits, stores, and visualises study subject data in clinical trials.
PAREXEL’s offering, powered by the Perceptive MyTrials® Analytics platform, enables an end-to-end services and technology solution that facilitates the remote collection of study subject data via medical devices. Collection of clinical data via wearables and sensors could replace or reduce the number of clinical assessments and/or on-site visits during clinical trials. This could potentially reduce the burden on trial participants and sites as well as decrease trial costs. Wearable monitoring solutions also allow data to be collected more often. Frequent collection of this data can provide real-time meaningful insights into a study subject’s behavior and health outside of visits, supporting better compliance and real-time user feedback.
PAREXEL’s clinical trial expertise and the ability to collect sensor-based data is designed to create efficiencies for sponsors, eliminating the need to contract separately for wearable third party devices to leverage sensors in a clinical study. According to Frost and Sullivan, the global market for wearables in healthcare is expected to reach $18.9 billion in 2020[1].
“Due to evolving regulatory and payer standards in today’s healthcare market, there is a growing need to leverage alternative data sources in clinical trials. Wearables and sensors have the potential to transform Phase I-IV trials as well as observational studies. However, infrastructure and multi-functional expertise are needed to validate the appropriate use of medical devices to generate clinical and quality-of-life endpoints,” said Xavier Flinois, President, PAREXEL Informatics. “PAREXEL’s offering could disrupt the industry standard of collecting data during site visits only, allowing biopharmaceutical sponsors to more easily demonstrate safety and/or efficacy and differentiate treatments from competition using remote monitoring approaches.”
The PAREXEL® patient sensor solution supports the generation of real-world data that can demonstrate value beyond the data collected during site visits. To deliver this solution, the Company has partnered with technology providers, including OSIsoft, to capture, securely transmit, store, and monitor data, as well as generate alerts based on the potentially large volume of time-series data from sensors.
The patient sensor solution is a complementary extension of PAREXEL''s current services, and is available through the Perceptive MyTrials® platform. It is also available through the Company''s PAREXEL Partner Program. For more information, please visit: https://www.parexel.com/solutions/informatics/patient-sensors.
[1]Wearable Technologies in Clinical and Consumer Health Report, Frost & Sullivan, March 2016
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
About PAREXEL International
PAREXEL International Corporation is a leading global biopharmaceutical services company, providing a broad range of expertise-based clinical research, consulting, medical communications, and technology solutions and services to the worldwide pharmaceutical, biotechnology, and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialisation continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, and reimbursement. PAREXEL Informatics provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL has offices in 85 locations in 51 countries around the world, and had approximately 19,625 employees in the second quarter. For more information about PAREXEL International visit www.PAREXEL.com.
Contacts:
Media:
Dana Robie
Tel.: +1 781-434-4772
Email: Dana.Robie(at)PAREXEL.com
Jenny Radloff, PAN Communications
Tel.: +1 617-502-4300
Email: PAREXEL(at)pancomm.com
Ivelina Adzheva
OneChocolate for PAREXEL
Tel: +44 (0)20 7437 0227
Email: parexel(at)onechocolatecomms.co.uk
Investors:
Ronald Aldridge
Tel.: +1 781-434-4753
Email: Ron.Aldridge(at)PAREXEL.com
Datum: 30.03.2017 - 10:58 Uhr
Sprache: Deutsch
News-ID 1495778
Anzahl Zeichen: 3245
contact information:
Contact person: RealWire
Town:
Lincoln
Phone: +44 (0)1522 883 640
Kategorie:
Healthcare & Medical
Typ of Press Release: bitte
type of sending: Veröffentlichung
Date of sending:
Anmerkungen:
Diese Pressemitteilung wurde bisher 513 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"PAREXEL Launches Patient Sensor Solution To Transform Clinical Trial Data Collection
"
steht unter der journalistisch-redaktionellen Verantwortung von
RealWire (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
